Desensitization in Kidney Allograft Using Daratumumab

Inclusion Criteria: * Adults ≥ 18 years awaiting a kidney allograft transplantation * Registration on the French National kidney allograft waiting-list for at least three years * cPRA ≥ 95% for at least three years * COVID-19 vaccination using Pfizer BioNtech vaccine for: Patients who have never been infected with COVID-19, inclusion at least one month after the third dose OR Patients previously infected with COVID-19 proved with PCR or serology, inclusion at least one month after the second injection of Pfizer BioNtech vaccine. * Effective contraception up to three months after the end of treatment * Informed consent obtained in accordance with local regulations; * Affiliation to a social security regime. Exclusion Criteria: * Refusal of COVID-19 vaccination using Pfizer BioNtech vaccine * Hypersensitivity to daratumumab or to any of the excipients), * Known allergy to methylprednisolone and its excipients or to diphenhydramine and its excipients or to acetaminophen and its excipients or to valacyclovir and its excipients. * Severe hepatocellular insufficiency * Psychotic state not yet controlled by treatment * Patient refusal * Pregnant or breastfeeding woman or ineffective contraception * Active neoplasia * Active infection * Active HBV infection, including HBsAg positive at screening * Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants * Persons deprived of their liberty by judicial or administrative decision, * Persons under legal protection/safeguard of justice, * Patients under duress psychiatric care, * Persons admitted to a health or social institution * Patient on AME (state medical aid) * Contraindication to kidney transplantation